<DOC>
	<DOCNO>NCT00953511</DOCNO>
	<brief_summary>RATIONALE : The prognosis patient advanced esophageal cancer may improve preoperative chemoradiation . But patient benefit additional therapy , whose tumor show response chemoradiation . Molecular marker may help identify start therapy patient response . PURPOSE : This first prospective , clinical trial study impact ERCC1 predict histopathological response neoadjuvant radiochemotherapy ( RTx/CTx ) patient cancer esophagus .</brief_summary>
	<brief_title>Cologne Esophageal Response Prediction Study ( CERP-Study )</brief_title>
	<detailed_description />
	<mesh_term>Esophageal Neoplasms</mesh_term>
	<criteria>informed consent newly diagnose adenocarcinoma squamous cell carcinoma esophagus cardia miss informed consent prior radiation chemotherapy second malignancy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>esophagus</keyword>
	<keyword>chemoradiation</keyword>
	<keyword>excision repair cross-complementing gene</keyword>
	<keyword>polymorphism</keyword>
	<keyword>response prediction</keyword>
</DOC>